Tuesday, January 9, 2018
There are many tools that can help suggest the presence of food allergies, but, in the end, the most reliable procedure to confirm or exclude a diagnosis of food allergy remains the oral challenge. But how should allergists perform them? In this month’s issue of JACI, Drs. Ballmer-Weber and Beyer provide their insights on how to effectively conduct a food challenge (J Allergy Clin Immunol 2018; 141(1): 69-71). The majority of children with food allergies require such challenges to diagnose their condition, especially younger children with eczema who have skin prick or blood tests suggesting that allergic sensitization may be a trigger for eczema flares, or in whom a food allergy may no longer be present. However, not all patients should have challenges. The risks of a severe, life-threatening anaphylactic reaction have to be balanced with the benefits of more definitively establishing a diagnosis. In addition, the risks of an oral challenge may be too high in those who are pregnant, have unstable asthma, or take medications that would interfere with the treatment of challenge-induced allergic reactions, such as Beta-blockers. The presence of other conditions, like hives, uncontrolled eczema, allergic rhinitis, mast cell disorders, or acute infection may make interpretation of results difficult and therefore influence an allergist’s decision to pursue an oral challenge. Regardless, a very careful examination is necessary beforehand. Once the decision is made, increasing doses of a particular food are given, usually every 30 minutes, but there is considerable flexibility in the amount of food, number of steps, and the time in between each step. Throughout the challenge, patients have to be monitored. If there are any objective signs of food allergy, the challenge should be stopped and treatment started. If the patient tolerates the challenge with no reaction, then the food should be taken at least three times per week to maintain tolerance. Although it is the most accurate tool that the allergist has, false-positive results do occur, in as many as 1 out of 25 challenges. False-negative results can also occur, especially if the food allergy tends to occur with an additional cofactor which was not accounted for in the challenge, like alcohol use, exercise, or viral infection. In conclusion, oral challenges are a powerful tool to identify food allergies, but safety always comes first and results have to be placed in their right clinical contexts.
The rate of food allergies in the United States keeps on rising, but nobody really knows the exact reasons why. In this month’s issue of the Journal of Allergy and Clinical Immunology, Du Toit and colleagues review the literature and focus on the ‘dual allergen’ hypothesis (J Allergy Clin Immunol 2018; 141(1): 30-40). Briefly, they explain that allergic sensitization may occur when there is low-level skin exposure to food allergens, while tolerance is more likely to develop in children to have early exposures to food proteins. The data are mounting from both animal and human observational studies as well as randomized control studies. The most notable has been the LEAP study, which showed that infants aged 4 to 11 months who consumed peanut products at least three times per week until age 60 months were far less likely to develop peanut allergies than infants who had complete avoidance. Only 3.2% in the peanut-eating group developed peanut allergy, compared to 17.2% in the complete avoidance group. The follow-up study, LEAP-On, demonstrated persistence of this tolerance for at least 12 months, even with strict avoidance in non-peanut allergic children. Similarly, the EAT study suggested that lower rates of food allergies with early introduction of allergenic foods in breastfed infants, although conclusions were less clear-cut than in the LEAP study. The results of other studies have been more variable. Regardless, the LEAP and EAT studies show that early introduction of allergenic foods into infant diet is achievable and safe, and does not affect breastfeeding rates as well as later nutrition and growth. However, there are a lot of challenges. Ensuring adherence to dietary recommendations, determining the dosages of food proteins, and powering studies sufficiently to show meaningful differences are challenges that researchers and clinicians face. This has led to the National Institutes of Health’s recommendation for early peanut introduction to prevent peanut allergy. Other countries have also recommended inclusion of potential common food allergens in complementary feeding regimens at around 6 months. With more research, it is possible that we may find more effective ways to help prevent food allergies.
Thursday, October 26, 2017
Asthma affects about 1 in 11 American children, making it one of the most common diseases of childhood. It carries a huge burden on families, especially during exacerbations when disease activity suddenly flares, leading to breathlessness and even death. In this month’s issue of JACI, Hoch and colleagues discuss their research in validating the Seasonal Asthma Exacerbation Predictive Index, the saEPI (J Allergy Clin Immunol 2017; 140(4): 1130-1137). The saEPI is a score ranging from 0 to 16 that can help predict how likely a child is to have an asthma flare. Using data from the Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study, they looked at 348 children randomized to two groups: one with omalizumab, and another with guideline-based therapy alone. They then calculated and validated the saEPI, moreover the authors looked at other factors that were associated with exacerbations. In short, they found that children who required more aggressive treatment (high doses of inhaled corticosteroids), had higher blood eosinophils, and were younger were more likely to have a flare. The saEPI, on the other hand, was better at determining which children were unlikely to have an asthma exacerbation. The authors encourage providers to use data such as this to personalize their care of children at risk for asthma exacerbations. Because the children that were part of the PROSE study were largely from inner-city and minority populations and the study inclusion criteria limited some children from particpating, a similar analysis should also be performed in a more general population of children, as well as adults. Regardless, the researchers conclude by noting the importance of such an index in managing children with asthma until even better methods are identified to classify children with asthma at risk for an asthma exacerbation.
Wednesday, October 25, 2017
Wheezing is a common complaint among parents of infants. About 1 in 5 children have acute wheezing illnesses in their first two years of life. This is important because an overwhelming majority of these wheezing illnesses are related to viruses, and are linked to asthma development. In this month’s issue of JACI, Jartti and Gern review the role of viral infections in the development of asthma in children (J Allergy Clin Immunol 2017; 140(4): 895-906).
They survey the viruses -rhinoviruses, respiratory syncytial viruses, and others – and how they impact the developing set of lungs. Genetic variation and low interferon responses are two factors that increase the risk of these types of infections. In addition, increased eosinophil counts in blood and nasal mucus and atopic eczema all increase the risk of later asthma.
Additionally, viral infections can lead to exacerbations in children who already have asthma. This may explain why the rates of asthma exacerbations are higher during the fall and winter, and why omalizumab, a potent medication for asthma control, may help to prevent exacerbations due to viruses like rhinovirus. The authors conclude that these insights may allow for new strategies to help prevent and manage viral wheezing illnesses so that they don’t lead to and worsen later asthma.
Tuesday, October 24, 2017
There are hundreds of viruses that cause respiratory tract infections. While most of us think about them as nuisances causing cough and wheezing, they bear a huge toll on health, especially in people who have lung diseases like asthma and COPD, as well as an economic toll in lost workdays and inappropriate use of medical resources. In this month’s issue of JACI, Papadopoulos and colleagues look at the treatment and prevention of these diseases (J Allergy Clin Immunol 2017; 140(4): 921-932).
They look at new medications that target the specific viruses in their reproductive phases. In addition, they review how natural products like echinacea can prevent recurrent respiratory tract infections. On the other side, there are promising insights about the use of immunostimulators in order to boost the body’s own responses to these viruses. Vitamin D, probiotic supplements, exercise and meditation are all helpful in resolving these infections. But perhaps the most promising strategies are in prevention, where vaccines are being developed to prime the immune system to fight against viruses. Currently, vaccines are available only against influenza virus. There are other developments on the horizon and may have a tremendous effect on addressing these diseases. The authors conclude that multiple strategies are necessary and that there may be tremendous benefits in such research, especially when it comes to dealing with more severe diseases that can cause epidemics and pandemics.
Tuesday, September 19, 2017
Diagnostic accuracy of fractional exhaled nitric oxide in predicting cough variant asthma and eosinophilic bronchitis in adult patients with chronic cough: A systematic review and meta-analysis
Cough is an important reflex we need to remove irritants from the airways, but for many people, a hypersensitive cough reflex can negatively affect quality of life. A major trigger of chronic cough is airway inflammation from immune cells including type 2 helper T-cells (TH2), but conventional tests required for diagnosis are technically challenging and often require specialist expertise. Fortunately, measurement of the fractional exhaled nitric oxide (FENO), a potential marker of TH2 airway inflammation, has become much more common in allergy and pulmonary practices. In this month’s issue of JACI, Song and colleagues review the literature on the use of FENO to diagnose Cough-Variant Asthma (CVA) and Eosinophilic Bronchitis (EB), two major causes of TH2-mediated chronic cough (J Allergy Clin Immunol 2017; 140(3): 701-709).
They looked at thousands of articles from multiple databases in order to answer the question “What is the diagnostic accuracy of FENO for CVA and/or EB in patients with chronic cough?” After an exhaustive search, they found 15 studies with 2187 adult patients. The authors then collected and compared the data to determine the accuracy. Overall, when looking at either CVA or EB, the pooled sensitivity and specificity were 0.73 and 0.89. For diagnosing CVA, they found moderate diagnostic accuracy, suggesting that the FENO test alone is not sufficient to diagnose CVA. However, its high specificity means that it may be more useful as a rule-in test than as a rule-out test. In contrast, results for EB suggested that FENO testing may not be precise enough for prediction.
This article provides guidance on how to further research on how best to use FENO testing in patients with chronic cough. However, there remain many unanswered questions because of limitations of the review, including the limited number of studies, generalizability of studies which were mostly conducted in Asia, and the imprecision of current diagnostic criteria for CVA.
Tuesday, September 12, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients
Asthma is a complex disease of the airways characterized by inflammation and dynamic airway obstruction. Despite the single, more recent evidence suggests that asthma is mediated by a set of distinct immune abnormalities. In this month’s issue of JACI, Silkoff and colleagues report the results of the ADEPT (Airways Disease Endotyping for Personal Therapeutics) study, in which 83 patients with mild, moderate, and severe asthma as well as 25 healthy non-asthmatic subjects were examined for biomarkers of asthma (J Allergy Clin Immunol 2017; 140(3): 710-719). They underwent bronchoscopy to obtain tissue samples, and then had the biomarkers measured in the lab to characterize them as having either high or low levels of type 2 inflammatory mediators. These were then correlated with clinical variables.
They determined the presence of type 2 inflammation based on airway expression of CCL26, periostin, and IL-13 in vitro signature (IVS). They then looked at the clinical variables, including fraction of exhaled nitric oxide (FENO) levels, blood eosinophil counts, serum CCL26 expression and serum CCL17 expression. What they found was that the combination of Fractional Excretion of Nitric Oxide (FENO), blood eosinophil counts, serum CCL17 and serum CCL26 had a positive predictive value of 100% for patients determined to be in the asthma group driven by type 2 inflammation. This is important because individual clinical characteristics alone could not predict the pattern of type 2 inflammatory markers, and eosinophilic inflammation was associated with , but not limited to, gene expression for type 2 inflammation in airways.
By describing a set of relatively easily obtainable clinical markers consistent with type 2 inflammation, the authors report information that can help researchers and practitioners tailor the most appropriate therapy for those with asthma mediated by type 2 inflammation.